Oslo University Hospital

Running trials

• Not yet recruiting

  Reconsidering Long-Term Apirin in the Elderly in Secondary Prevention of Coronary Artery Disease Norway

  NCT07854795· Phase 4· Source

• Not yet recruiting

  Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome

  NCT07360834· Source

• Recruiting

  Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial

  NCT07922967· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.

  2026-525367-40-00· Phase 3· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Source

• Not yet recruiting

  Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies

  NCT07878208· Source

• Recruiting

  Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

  NCT07473843· Phase 3· Source

• Not yet recruiting

  Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE

  NCT07870681· Phase 2/3· Source

• Not yet recruiting

  bNAbs and Anti-PD-1 in HIV

  NCT07820813· Phase 2· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Source

• Recruiting

  A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.

  2025-523285-25-00· Phase 3· Source

• Recruiting

  Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation

  NCT07436299· Source

• Not yet recruiting

  Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.

  NCT07757412· Phase 2· Source

• Enrolling by invitation

  Donor Derived Cell Free DNA (Dd-cfDNA) as a Biomarker for Allograft Rejection in Heart Transplant Recipients

  NCT07886489· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· Source

• Not yet recruiting

  A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

  2025-524439-38-00· Phase 2· Source

• Not yet recruiting

  Reassessment of statin-associated muscle symptoms in adults with familial hypercholesterolemia

  2025-521589-83-00· Phase 4· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Phase 2· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Source

• Enrolling by invitation

  Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

  NCT07102511· Phase 3· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

  NCT07672236· Phase 3· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Source

• Recruiting

  A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer

  2025-522818-23-00· Phase 3· Source

• Recruiting

  Prospective Natural History Study of POLG Disease

  NCT07775872· Source

• Recruiting

  A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

  2026-525543-32-00· Phase 1· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Source

• Recruiting

  MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis

  NCT07444047· Source

• Recruiting

  Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.

  NCT07580300· Phase 3· Source

• Recruiting

  Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging

  NCT07602010· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Not yet recruiting

  A randomized placebo-controlled double-blind trial phase II two-arm study to investigate infarct growth over 72 hours assessed with diffusion weighted imaging on MRI after treatment with intravenous tocilizumab or placebo in patients above 18 years of age with acute ischemic stroke undergoing endovascular thrombectomy.

  2025-521269-28-00· Phase 2· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )

  2024-519818-31-01· Phase 3· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Source

• Recruiting

  Optimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control Trial

  NCT07255066· Source

• Recruiting

  Selenium Intervention Registry Randomized Trial in Heart Failure

  NCT07543562· Phase 3· Source

• Recruiting

  Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy

  NCT07144319· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Source

• Not yet recruiting

  Mechanisms Of Change in Psychotherapy: The Effects of Cognitive Behavioral Therapy and Psychodynamic Therapy in Once - Versus Twice - Weekly Sessions on Outcomes in Depression.

  NCT07408687· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Source

• Recruiting

  A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

  NCT07298044· Phase 4· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Source

• Recruiting

  Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma

  NCT07169344· Phase 2· Source

Showing 50 of 209.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma11 recruiting
• Pancreatic cancer10 recruiting
• Lung cancer9 recruiting
• Childhood cancers8 recruiting
• Colorectal cancer8 recruiting
• Heart failure8 recruiting
• Liver and biliary tract cancer8 recruiting
• Prostate cancer7 recruiting
• Head and neck cancer5 recruiting
• Melanoma5 recruiting
• Bladder cancer4 recruiting
• Endometrial cancer4 recruiting
• High blood pressure4 recruiting
• Migraine4 recruiting
• Ovarian cancer4 recruiting
• Stroke4 recruiting
• Atrial fibrillation3 recruiting
• Bipolar disorder3 recruiting
• Coronary artery disease3 recruiting
• Familial hypercholesterolaemia3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Myelodysplastic syndromes3 recruiting
• Sarcoma3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Acute myeloid leukaemia2 recruiting
• ALS (motor neurone disease)2 recruiting
• Amyloidosis2 recruiting
• Autism2 recruiting
• Cervical cancer2 recruiting
• Crohn's disease2 recruiting
• Glioblastoma2 recruiting
• Huntington's disease2 recruiting
• Metastatic breast cancer2 recruiting
• Multiple sclerosis2 recruiting
• Neuroendocrine tumours2 recruiting
• Schizophrenia2 recruiting
• Thyroid cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Cystic fibrosis1 recruiting
• Depression1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Glaucoma1 recruiting
• Haemophilia1 recruiting
• HIV1 recruiting
• Lupus (SLE)1 recruiting
• Obesity1 recruiting
• Parkinson disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Retinitis pigmentosa1 recruiting
• Rheumatoid arthritis1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

  NCT07444450· Phase 3· Source

• Completed

  Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer

  NCT06947382· Source

• Active, not recruiting

  Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

  NCT06151574· Phase 3· Source

• Terminated

  Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy

  NCT06290856· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Source

• Terminated

  Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

  NCT05609942· Phase 1· Source

• Completed

  Nevoid Basal Cell Carcinomas in Gorlin Syndrome

  NCT05898347· Source

• Completed

  Ultrasound for Detection of Prostate Cancer

  NCT05736094· Source

• Terminated

  Home Blood Pressure Monitoring in Kidney Transplant Recipients

  NCT04364126· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Source

• Completed

  Blood Flow Restriction Exercise in Patients With Pancreatic, Biliary Tract, and Liver Cancer (PREV-Ex)

  NCT05044065· Source

• Completed

  A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

  NCT05243342· Phase 1· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Source

• Completed

  New-onset Severe Headache After Covid-19 Vaccine

  NCT05235776· Source

• Completed

  Zoledronate Early to Hip Fracture Patients - Safe and Effective?

  NCT05025293· Phase 4· Source

• Completed

  A Complex Intervention for Chronically Fatigued Lymphoma Survivors

  NCT05130099· Source

• Completed

  The Oslo Study of Visual Impairment After Stroke (StrokeVIS)

  NCT05809973· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Source

• Completed

  NETwork of Linoleic Acid Supplementation in Cystic Fibrosis

  NCT04531410· Source

• Completed

  Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)

  NCT04304755· Phase 2· Source

• Terminated

  HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.

  NCT04898504· Phase 2· Source

• Terminated

  Open-Label Surufatinib in European Patients With NET

  NCT04579679· Phase 2· Source

• Terminated

  A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

  NCT04740918· Phase 3· Source

• Terminated

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

  NCT04272034· Phase 1· Source

• Terminated

  Study to Evaluate Safety and Efficacy of IBsolvMIR in Islet Transplantation

  NCT03867851· Phase 2· Source

• Terminated

  A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients

  NCT04550897· Phase 1/2· Source

• Completed

  Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

  NCT04405349· Phase 2· Source

• Completed

  Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC

  NCT04275713· Phase 2· Source

• Completed

  A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease

  NCT03568968· Phase 3· Source

• Completed

  Boosting Biologics in UC

  NCT04241029· Source

• Completed

  Radiotherapy of Head and Neck Cancer Using an Intraoral Stent

  NCT04330781· Phase 2· Source

• Completed

  Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

  NCT04934800· Source

• Completed

  The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study

  NCT04122235· Source

• Completed

  Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)

  NCT04121403· Phase 3· Source

• Completed

  CIRSE Emprint Microwave Ablation Registry

  NCT03775980· Source

• Completed

  Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

  NCT03556839· Phase 3· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· Source

• Terminated

  Study of Antithrombotic Treatment After IntraCerebral Haemorrhage

  NCT03186729· Phase 4· Source

• Terminated

  Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window

  NCT03094715· Source

• Completed

  METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin

  NCT03388190· Phase 2· Source

• Completed

  Fibrosis, Inflammation and Brain Health in Atrial Fibrillation.

  NCT03816865· Source

• Terminated

  "Watch and Wait" After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer.

  NCT03402477· Source

• Completed

  Aspirin in Colorectal Cancer Liver Metastases

  NCT03326791· Phase 2/3· Source

• Completed

  A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

  NCT03267316· Phase 1/2· Source

• Completed

  BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

  NCT02872259· Phase 1/2· Source

• Completed

  Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III

  NCT02978612· Phase 2· Source

• Completed

  Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

  NCT02684708· Phase 3· Source

• Completed

  Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT02205047· Phase 2· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Source

Showing 50 of 52.

Trial sites

• Oslo University Hospital1 trial
• Department of Medical Oncology Oslo University Hospital1 trial
• Department of Nephrology, Oslo University Hospital1 trial
• Department of Neurohabilitation, Oslo University Hospital1 trial
• Department of Neurology, Oslo University Hospital1 trial
• Department of Ophthalmology, Oslo University Hospital2 trials
• Department of vascular surgery, Oslo University Hospital1 trial
• Dept. of Neurology, Oslo University Hospital0 trials
• Division of Cardiovascular & Pulmonary Diseases, Oslo University Hospital1 trial
• ENT department, Oslo University Hospital1 trial
• Nevroklinikken Universitetet i Oslo, Oslo Universitetssykehus HF0 trials
• Norwegian Resourse Center for Cystic Fibrosis, Oslo University Hospital1 trial
• Nydalen DPS, Division of Mental Health and Addiction, Oslo University Hospital1 trial
• Oslo Myeloma Center, Oslo University Hospital1 trial
• Oslo Universitetssykehus HF56 trials
• Oslo Universitetssykehus HF, Radiumhospitalet4 trials
• Oslo universitetssykehus HF, Rikshospitalet4 trials
• Oslo universitetssykehus HF, Ullevål3 trials
• Oslo Universitetssykehus HF, Ulleval sykehus0 trials
• Oslo universitetssykehus HF, Utprøvingsenheten1 trial
• Oslo University Hopital, Rikshospitalet1 trial
• Oslo University Hospital147 trials
• Oslo University Hospital - Aker1 trial
• Oslo University Hospital and University of Oslo2 trials
• Oslo University Hospital, Department of Cardiology, Rikshospitalet Sognsvannsveien 200 trials
• Oslo University Hospital, Department of Hematology1 trial
• Oslo University Hospital, Department of Neurology1 trial
• Oslo university hospital, Department of Ophthamology1 trial
• Oslo University Hospital, Department of Paediatric Medicine1 trial
• Oslo University Hospital, Department of radiation Therapy1 trial
• Oslo University Hospital, Department Urology1 trial
• Oslo University Hospital, Dept of Haematology1 trial
• Oslo University Hospital, Dept of paediatric haemato- and oncology1 trial
• Oslo University Hospital (Nydalen DPS and Søndre Oslo DPS)1 trial
• Oslo University Hospital, Oslo Myeloma Centre1 trial
• Oslo University Hospital - Paediatrics0 trials
• Oslo University Hospital - Radiumhospitalet8 trials
• OSLO UNIVERSITY HOSPITAL,RIKSHOPITALET (Data Collection Only)1 trial
• Oslo University Hospital, Rikshospitalet10 trials
• Oslo University Hospital, Rikshospitalet, Section of Nephrology1 trial
• Oslo University Hospital (Site 2001)0 trials
• OUS (Oslo University Hospital), Rikshospitalet0 trials
• Rikshospitalet, Oslo University Hospital2 trials
• Søndre Oslo DPS, Division of Mental Health and Addiction, Oslo University Hospital1 trial
• University Hospital Oslo2 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke142 works · 10 trials
• Heart failure103 works · 9 trials
• Colorectal cancer71 works · 21 trials
• Schizophrenia70 works · 2 trials
• Bipolar disorder55 works · 2 trials
• Prostate cancer53 works · 10 trials
• Epilepsy44 works · 1 trial
• Systemic sclerosis (scleroderma)37 works · 4 trials
• Coronary artery disease32 works · 5 trials
• Multiple myeloma31 works · 13 trials
• Depression31 works · 1 trial
• Ulcerative colitis31 works · 3 trials
• Type 1 diabetes26 works · 3 trials
• Rheumatoid arthritis25 works · 2 trials
• Sarcoma24 works · 4 trials
• Crohn's disease23 works · 2 trials
• Glioblastoma22 works · 4 trials
• Idiopathic pulmonary fibrosis19 works · 1 trial
• Migraine18 works · 5 trials
• Hodgkin lymphoma16 works · 0 trials
• Endometrial cancer13 works · 6 trials
• Acute lymphoblastic leukaemia13 works · 3 trials
• Familial hypercholesterolaemia12 works · 4 trials
• Macular degeneration12 works · 1 trial
• Childhood cancers10 works · 13 trials
• Myelodysplastic syndromes8 works · 4 trials
• Huntington's disease8 works · 2 trials
• Lewy body dementia8 works · 0 trials
• Haemophilia6 works · 2 trials
• Primary biliary cholangitis5 works · 0 trials